COMMUNIQUÉS West-GlobeNewswire

MacroGenics Announces Date of First Quarter 2025 Financial Results
06/05/2025
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
06/05/2025
Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25 New strategic collaboration with Lilly ExploR&D expands therapeutic approach to [...]
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
06/05/2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright [...]
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
06/05/2025
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), [...]
Cellectis publiera ses résultats financiers du premier trimestre le 12 mai 2025
06/05/2025
NEW YORK, 06 mai 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Cellectis to Report First Quarter Financial Results on May 12, 2025
06/05/2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025
06/05/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025
06/05/2025
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
06/05/2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the [...]
WW International, Inc. Schedules Investor Conference Call
06/05/2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, announced that it will host an investor [...]
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
06/05/2025
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete [...]
BetterLife Announces Debt Settlements
06/05/2025
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development of [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2025 Financial Results on May 8, 2025
06/05/2025
FREDERICK, Md., May 06, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Extendicare Announces 2025 First Quarter Results
06/05/2025
MARKHAM, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2025. First Quarter 2025 Highlights Adjusted [...]
WeightWatchers Takes Strategic Action to Eliminate $1.15 Billion of Debt, Strengthening Financial Position for Long-Term Growth and Profitability
06/05/2025
Operations continue with no impact to its more than three million members worldwide Positions the Company to execute its transformation strategy, focused on enhancing its digital and member experience and expanding its [...]
Dunham House Breaks Ground on Transformational Housing for Combat-Wounded Veterans
06/05/2025
OMAHA, Neb., May 06, 2025 (GLOBE NEWSWIRE) -- Between 2000 and 2019, the Defense and Veterans Brain Injury Center reported nearly 414,000 service members worldwide sustained a traumatic brain injury. In the same period [...]
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 [...]
Dogecoin Cash, Inc. Confirms Stock Dividend Record and Payment Dates; FINRA Publication Completed
07/05/2025
MESQUITE, NV, May 06, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the [...]
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
06/05/2025
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of [...]

Pages